Table 2.
Secondary Efficacy Outcome Measures, Week 8 (last observation carried forward), Intent-to-Treat Populationa
| MADRS |
CGI-S |
SDS |
WHO-5 |
||||||||||||||||
| Adjusted Mean Difference (95% CI) | P Value | Adjusted Mean Difference (95% CI) | P Value | Adjusted Mean Difference (95% CI) | P Value | Adjusted Mean Difference (95% CI) | P Value | ||||||||||||
| Desvenlafaxine 50 mg/d | |||||||||||||||||||
| Normal | −2.19 (–3.48 to –0.90) | .0009 | −0.27 (–0.42 to –0.11) | .0007 | −1.64 (–2.55 to –0.74) | .0004 | 1.16 (0.37 to 1.95) | .0040 | |||||||||||
| Overweight | −2.77 (–4.19 to –1.36) | .0001 | −0.31 (–0.49 to –0.14) | .0004 | −1.53 (–2.59 to –0.47) | .0047 | 0.89 (–0.04 to 1.83) | .0614 | |||||||||||
| Obese | −1.98 (−3.17 to –0.79) | .0012 | −0.20 (–0.34 to –0.06) | .0046 | −1.67 (–2.57 to –0.77) | .0003 | 1.40 (0.55 to 2.25) | .0012 | |||||||||||
| Desvenlafaxine 100 mg/d | |||||||||||||||||||
| Normal | −3.21 (–4.96 to –1.45) | .0004 | −0.44 (–0.65 to –0.23) | < .0001 | −1.80 (–3.02 to –0.58) | .0038 | 0.95 (–0.02 to 1.92) | .0548 | |||||||||||
| Overweight | −2.98 (–4.90 to –1.05) | .0025 | −0.27 (–0.51 to –0.04) | .0220 | −1.19 (–2.61 to 0.22) | .0989 | 1.66 (0.54 to 2.77) | .0037 | |||||||||||
| Obese | −2.69 (–4.50 to –0.87) | .0037 | −0.39 (–0.61 to –0.18) | .0004 | −2.37 (–3.72 to –1.02) | .0006 | 2.08 (1.03 to 3.12) | .0001 | |||||||||||
| (cont. below) | |||||||||||||||||||
| HDRS-17 Responseb | HDRS-17 Remissionc | |||||||||||||||||||||
| n/N (%) | P Value | n/N (%) | P Value | |||||||||||||||||||
| Desvenlafaxine 50 mg/d | ||||||||||||||||||||||
| Normal | 228/443 (51.5) | .001 | 124/443 (28.0) | .009 | ||||||||||||||||||
| Overweight | 188/398 (47.2) | .025 | 117/398 (29.4) | .230 | ||||||||||||||||||
| Obese | 274/580 (47.2) | .003 | 160/580 (27.6) | .008 | ||||||||||||||||||
| Desvenlafaxine 100 mg/d | ||||||||||||||||||||||
| Normal | 113/200 (56.5) | .014 | 75/200 (37.5) | < .001 | ||||||||||||||||||
| Overweight | 85/166 (51.2) | .025 | 53/166 (31.9) | .200 | ||||||||||||||||||
| Obese | 105/203 (51.7) | .018 | 58/203 (28.6) | .039 | ||||||||||||||||||
| Placebo | ||||||||||||||||||||||
| Normal | 191/479 (39.9) | 91/479 (19.0) | ||||||||||||||||||||
| Overweight | 146/396 (36.9) | 94/396 (23.7) | ||||||||||||||||||||
| Obese | 192/519 (37.0) | 99/519 (19.1) | ||||||||||||||||||||
a
BMI categories: normal = BMI ≤ 25 kg/m2, overweight = 25 kg/m2 < BMI ≤ 30 kg/m2, obese = BMI > 30 kg/m2.
b
≥ 50% reduction from baseline in HDRS-17 total score.
c
HDRS-17 total score ≤ 7.
Abbreviations: BMI = body mass index, CGI-S = Clinical Global Impressions Scale–Severity, HDRS-17 = 17-item Hamilton Depression Rating Scale, MADRS = Montgomery-Asberg Depression Rating Scale, SDS = Sheehan Disability Scale, WHO-5 = World Health Organization 5-item Well-Being Index.